ArticleScientific reports2026
A dual-drug chitosan-hyaluronic acid bandage contact lens accelerates corneal re-epithelialization in a rabbit mechanical debridement model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid corneal re-epithelialization is crucial to prevent infection and scarring, yet the efficacy of conventional topical therapies is hindered by their limited ocular bioavailability. To address this, we developed a daily replaceable chitosan-hyaluronic acid (CS-HA) bandage contact lens co-loaded with levofloxacin and betamethasone using a soaking-based drug-loading approach. In a rabbit 8-mm mechanical corneal debridement model (n = 15/group), the dual-drug CS-HA lens was compared with a chitosan-only drug-loaded lens, a commercial silicone-hydrogel bandage lens plus drops, and drops alone. The CS-HA lens maintained adequate optical transparency, water content, and oxygen permeability suitable for short-term wear. In vitro assays showed that the dual-drug CS-HA lens retained antibacterial inhibitory activity in agar diffusion tests and reduced TNF-α secretion in an LPS-stimulated THP-1 assay. Re-epithelialization was significantly faster with the CS-HA lens, achieving complete closure at a median of 3 days versus 5, 6, and 8 days in the respective control groups. Day-10 histology showed a well-stratified epithelium with no evidence of stromal inflammatory infiltration in the CS-HA group, whereas controls exhibited greater stromal disorganization. This biocompatible dual-drug platform may accelerate ocular surface restoration and reduce reliance on frequent topical dosing in settings such as post-refractive surgery care and persistent epithelial defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.